texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Request an Appointment

Clinical Publications and Presentations

PUBLICATION TITLE
First- Line Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX for Metastatic Pancreatic Cancer in a Real-World Population.
PUBLICATION
Future Oncology
CITATION
Future Oncol . 2022 Jun;18(20):2521-2532.
CLINICIANS
Hatashima A, Arango M, Reardon J, Freeman T, Williams T, McLaughlin E, Abushahin L.
PUBLICATION TITLE
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Idehntifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
PUBLICATION
Frontier Immunology
CITATION
Front Immunol . 2022 Apr 26;13:779691.
CLINICIANS
Chennamadhavuni, Abushahin L, Jin N, Presley C, Manne A.
PUBLICATION TITLE
Surgical Treatment of Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma: An Analysis of the National Cancer Database
PUBLICATION
Surgery
CITATION
Surgery . 2022 Jun;171(6):1464-1470.
CLINICIANS
Hamad A, Underhill J, Ansari A, Thayaparan V, Cloyd J, Li Y, Pawlik T, Tsung A, Abushahin L, Aslam Ejaz.
PUBLICATION TITLE
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
PUBLICATION
The New England Journal of Medicine.
CITATION
N Engl J Med . 2022 Dec 13.
CLINICIANS
Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Habte A Yimer, et al.
PUBLICATION TITLE
Zanubrutinib in Patients with Previously Treated B-cell Malignancies Intolerant of Previous Bruton Tyrosine Kinase Inhibitors in the USA: A Phase 2, Open-Label, Single-Arm Study
PUBLICATION
The Lancet Hematology
CITATION
Lancet Haematol . 2023 Jan;10(1):e35-e45
CLINICIANS
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Habte A Yimer, et al.
PUBLICATION TITLE
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
PUBLICATION
Journal of Clinical Oncology
CLINICIANS
Peter Hillmen, MBChB, PhD1, Barbara Eichhorst, MD2, Jennifer R. Brown, MD, PhD, Habte A Yimer, M.D., et al.
PUBLICATION TITLE
Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone For Multiple Myeloma: Final Results of The LYRA Study
PUBLICATION
Leukemia & Lymphoma
CLINICIANS
Habte Yimer, Jason Melear, Edward Faber, Habte A Yimer, et al.
PUBLICATION TITLE
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
PUBLICATION
American Society of Hematology
CLINICIANS
Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Tatyana Feldman, Habte Yimer, et al.
PUBLICATION TITLE
Genomic Characterization of Patients in A Phase 2 Study of Zanubrutinib in BTK Inhibitor–Intolerant Patients With Relapsed/Refractory B-Cell Malignancies
PUBLICATION
American Society of Hematology
CLINICIANS
Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Habte Yimer, et al.
PUBLICATION TITLE
Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient or Inpatient Treatment in The Community/Nonuniversity Setting in Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL
PUBLICATION
American Society of Hematology
CLINICIANS
Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Habte Yimer, et al.
Displaying results 31-40 (of 1819)
 <  1 2 3 4 5 6 7 8 9 10  > 

* Texas Oncology Clinicians